$15.51
0.020.14%
Pre-Market: 4:39 PM EDT
Comments
Loading...
Teva Pharmaceutical Indus Stock Guidance | NYSE:TEVA | Benzinga
Teva Pharmaceutical Indus issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/27/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.35 | $2.65 | $2.54 | $16.80B | $17.40B | $17.14B | Get Alert |
| 03/27/2025 | TEVA | Teva Pharmaceutical Indus | Q1 | 2025 | $0.52 | $0.52 | $0.48 | $3.99B | $3.99B | $3.98B | Get Alert |
| 01/29/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.35 | $2.65 | $2.78 | $16.80B | $17.40B | $17.09B | Get Alert |
| 11/06/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.40 | $2.50 | $2.45 | $16.10B | $16.50B | $16.26B | Get Alert |
| 07/31/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.30 | $2.50 | $2.34 | $16.00B | $16.40B | $16.01B | Get Alert |
| 05/08/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.20 | $2.50 | $2.41 | $15.70B | $16.30B | $15.86B | Get Alert |
| 01/31/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.20 | $2.50 | $2.42 | $15.70B | $16.30B | $15.57B | Get Alert |
| 11/08/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.28 | $15.10B | $15.50B | $15.14B | Get Alert |
| 08/02/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.27 | $15.00B | $15.40B | $15.02B | Get Alert |
| 05/10/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.40 | $14.80B | $15.40B | $15.06B | Get Alert |
| 02/08/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.52 | $14.80B | $15.40B | $15.23B | Get Alert |
| 11/03/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | $2.50 | $14.80B | $15.40B | $15.46B | Get Alert |
| 07/26/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | — | $15.00B | $15.60B | $15.67B | Get Alert |
| 05/03/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | $2.51 | $15.40B | $16.00B | $15.97B | Get Alert |
| 02/09/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | $2.64 | $15.60B | $16.20B | $16.32B | Get Alert |
| 10/27/2021 | TEVA | Teva Pharmaceutical Indus | FY | 2021 | $2.50 | $2.70 | $2.58 | $16.00B | $16.40B | $16.30B | Get Alert |
| 07/28/2021 | TEVA | Teva Pharmaceutical Indus | FY | 2021 | $2.50 | $2.70 | $2.45 | $16.00B | $16.40B | $16.55B | Get Alert |
| 04/28/2021 | TEVA | Teva Pharmaceutical Indus | FY | 2021 | $2.50 | $2.70 | $2.61 | $16.40B | $16.80B | $16.68B | Get Alert |
| 02/10/2021 | TEVA | Teva Pharmaceutical Indus | FY | 2021 | $2.50 | $2.70 | $2.63 | $16.40B | $16.80B | $16.76B | Get Alert |
| 11/05/2020 | TEVA | Teva Pharmaceutical Indus | FY | 2020 | $2.40 | $2.55 | $2.51 | $16.50B | $16.80B | $16.69B | Get Alert |
| 08/05/2020 | TEVA | Teva Pharmaceutical Indus | FY | 2020 | $2.30 | $2.55 | $2.50 | $16.60B | $17.00B | $16.80B | Get Alert |
FAQ
What is the most recent guidance for Teva Pharmaceutical Indus (TEVA)?
The most recent guidance for Teva Pharmaceutical Indus (TEVA) was reported on March 27, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $2.35 to $2.65, compared to the estimated EPS of $2.54. Additionally, Teva Pharmaceutical Indus forecasted revenue between $16.80B and $17.40B for the quarter.
Browse guidance and forecast on all stocks.